Literature DB >> 17422730

Erythrocyte osmotic fragility testing and the prediction of canine malignant hyperthermia susceptibility.

P H Cribb, E A Olfert, F B Reynolds.   

Abstract

A Doberman-German Shepherd cross-bred male dog, previously diagnosed as malignant hyperthermia susceptible, was mated to an unrelated nonsusceptible German Shepherd cross-bred female. The resultant litter was subjected to hematological, biochemical and erythrocyte osmotic fragility testing in an endeavor to predict the susceptibility of individuals to malignant hyperthermia. Laboratory evaluations were repeated at one year of age and the litter subjected to the halothane challenge test. No significant difference in erythrocyte osmotic fragility was found between malignant hyperthermia susceptible and nonsusceptible siblings at six weeks or at one year of age. Erythrocyte osmotic fragility, in both malignant hyperthermia susceptible and nonsusceptible animals, increased between six weeks and one year of age. Dantrolene sodium was an effective treatment for malignant hyperthermia in the dog when administered early in an episode and in adequate dosage. The initial sign of a malignant hyperthermia episode was a very rapid increase in end tidal partial pressure of carbon dioxide. This finding reinforces the value of capnographic monitoring in anesthesia.

Entities:  

Year:  1986        PMID: 17422730      PMCID: PMC1680423     

Source DB:  PubMed          Journal:  Can Vet J        ISSN: 0008-5286            Impact factor:   1.008


  27 in total

1.  Screening of malignant hyperthermia susceptible families by creatine phosphokinase measurement and other clinical investigations.

Authors:  B A Britt; L Endrenyi; P L Peters; F H Kwong; L Kadijevic
Journal:  Can Anaesth Soc J       Date:  1976-05

2.  Retrospective analysis of anaesthetics received by patients before susceptibility to malignant hyperpyrexia was recognized.

Authors:  P J Halsall; P A Cain; F R Ellis
Journal:  Br J Anaesth       Date:  1979-10       Impact factor: 9.166

3.  Etiology and pathophysiology of malignant hyperthermia.

Authors:  B A Britt
Journal:  Fed Proc       Date:  1979-01

Review 4.  Malignant hyperthermia--pearls out of swine?

Authors:  G M Hall; J N Lucke; D Lister
Journal:  Br J Anaesth       Date:  1980-02       Impact factor: 9.166

5.  Malignant hyperthermia in a greyhound.

Authors:  C A Cohen
Journal:  J Am Vet Med Assoc       Date:  1978-06-01       Impact factor: 1.936

6.  Unusual reaction to suxamethonium chloride.

Authors:  L W Hall; N Woolf; J W Bradley; D W Jolly
Journal:  Br Med J       Date:  1966-11-26

7.  Malignant hyperthermia-like reactions in three anesthetized horses.

Authors:  S V Manley; A B Kelly; D Hodgson
Journal:  J Am Vet Med Assoc       Date:  1983-07-01       Impact factor: 1.936

8.  Canine malignant hyperthermia susceptibility: erythrocytic defects--osmotic fragility, glucose-6-phosphate dehydrogenase deficiency and abnormal Ca2+ homeostasis.

Authors:  P J O'Brien; G W Forsyth; D W Olexson; H S Thatte; P B Addis
Journal:  Can J Comp Med       Date:  1984-10

Review 9.  Malignant hyperthermia.

Authors:  G A Gronert
Journal:  Anesthesiology       Date:  1980-11       Impact factor: 7.892

10.  End-tidal partial pressure of CO2 as an estimate of arterial partial pressure of CO2 during various ventilatory regimens in halothane-anesthetized dogs.

Authors:  C E Hightower; A L Kiorpes; H C Butler; M R Fedde
Journal:  Am J Vet Res       Date:  1980-04       Impact factor: 1.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.